Journal List > J Korean Endocr Soc > v.21(5) > 1003319

TOOLS
Lee, Byun, Park, Oh, Hong, Sung, and Chung: Adiponectin and Ghrelin Polymorphism in Korean Women with Polycystic Ovary Syndrome
Original Article
Journal of Korean Endocrine Society

Journal of Korean Endocrine Society 2006; 21(5): 394-401.

Published online: 20 October 2006

DOI: https://doi.org/10.3803/jkes.2008.21.5.394

Adiponectin and Ghrelin Polymorphism in Korean Women with Polycystic Ovary Syndrome

Hyejin Lee, Eun Kyung Byun, Hwi Ra Park, Jee-Young Oh, Youngsun Hong, Yeon-Ah Sung, Hyewon Chung1

Department of Internal Medicine, Ewha Womans University College of Medicine, Korea.

1Department of Obstetrics and Gynecology, Ewha Womans University College of Medicine, Korea.

Received 17 May 2006       Accepted 31 July 2006

Copyright © 2006 Korean Endocrine Society

Abstract

Background

Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism and chronic anovulation, and this is a common disorder in premenopausal women. However, the pathogenesis is still uncertain. There has been no studies about PCOS-related genetic abnormalities in Korea. In this study, we examined the frequency of the adiponectin and ghrelin genotypes in Korean women with PCOS.

Methods

Fifty four women with PCOS and 174 regular cycling healthy women were recruited for the study, and their reproductive hormones and metabolic profiles were measured. The polymorphisms of the ghrelin and adiponectin genes were analyzed.

Results

The frequency of ghrelin gene polymorphism was not different between the women with PCOS and the controls. The frequency of the TG adiponectin genotype was higher and the frequency of the TT genotype was lower in the women with PCOS compared to the controls (P < 0.05). For the PCOS women with GG adiponectin genotype, their triglycerides levels were significantly higher compared to the PCOS women with the TT and TG genotypes even after adjusting for the BMI.

Conclusion

Adiponectin gene polymorphism is associated with presence of PCOS and it is responsible for the dyslipidemia seen in PCOS. Yet further study is required to confirm the role of this genetic polymorphism in the susceptibility to PCOS and the associated metabolic features.

Keywords: Adioponectin, Ghrelin, Polycystic ovary syndrome

Figures and Tables

Table 1
Clinical and biochemical characteristics in total subjects
jkes-21-394-i001

Data are mean ± SD.

DHEAS, dehydroepiandrosterone sulfate; FSH, follicle stimulating hormone; LH, luteinizing hormone; PCOS, polycystic ovary syndrome; SHBG, sex hormone binding globulin.

*P < 0.05 vs. control.

Table 2
Frequencies of ghrelin and adiponectin genotype in control and women with polycystic ovary syndrome (PCOS)
jkes-21-394-i002

*P < 0.05 by χ2 test.

Table 3
Clinical and biochemical characteristics according to adiponectin genotype in women with polycystic ovary syndrome
jkes-21-394-i003

Data are mean ± SD.

DHEAS, dehydroepiandrosterone sulfate; FSH, follicle stimulating hormone; LH, luteinizing hormone; SHBG, sex hormone binding globulin.

*P < 0.05 vs. TT.

†P < 0.05 vs. TG.

References

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapandi ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal metabolic profile. J Clin Endocrinol Metab. 1999. 84:4006 –4011.
2. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998. 83:3078–3082.
3. Zawadski JK, Dunaif A. Dunaif A, Givens JR, Haseltine F, editors. Diagnostic criteria for polycystic ovary syndrome; towards a rational approach. Polycystic Ovary Syndrome. 1992. Scientific, Boston: Blackwell;377–384.
4. Rotterdam ESHRE/ASRAM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004. 81:19–25.
5. Legro RS, Spielman R, Urbanek M, Driscoll D, Strauss JF 3rd, Dunaif A. Phenotype and genotype in polycystic ovary syndrome. Recent Prog Horm Res. 1998. 53:217–256.
6. Givens JR. Familial polycystic ovarian disease. Endocrinol Metab Clin North Am. 1988. 17:771–783.
7. Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A. 1998. 95:14956–14960.
8. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome-a hypothesis. J Endocrinol. 2002. 174:1–5.
9. Legro RS, Kunselman AR, Demers L, Wang SC, Bentley-Lewis R, Dunaif A. Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002. 87:2134–2138.
10. Gharani N, Waterworth DM, Batty S, White D, Gilling-Smith C, Conway GS, McCarthy M, Franks S, Willianmson R. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet. 1997. 6:397–402.
11. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Willliamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet. 1994. 3:1873–1876.
12. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995. 333:853–861.
13. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes. 1992. 41:1257–1266.
14. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest. 1995. 96:801–810.
15. Ciaraldi TP, el-Roeiy A, Madar Z, Reichart D, Olefsky JM, Yen SS. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab. 1992. 75:577–583.
16. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, Franks S. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol. 1992. 36:105–111.
17. Urbanek M, Legro RS, Driscoll DA, Azziz R, Ehrmann DA, Norman RJ, Strauss JF 3rd, Spielman RS, Dunaif A. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci U S A. 1999. 96:8573–8578.
18. Tena-Sempere M. Ghrelin: novel regulator of gonadal function. J Endocrinol Invest. 2005. 28:suppl 5. 26–29.
19. Barreiro ML, Tena-Sempere M. Ghrelin and reproduction: a novel signal linking energy status and fertility. Mol Cell Endocrinol. 2004. 29:1–9.
20. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, Bloom SR. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001. 86:5992.
21. Schofl C, Horn R, Schill T, Schlosser HW, Muller MJ, Brabant G. Circulating ghrelin levels in patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002. 87:4607–4610.
22. Gambineri A, Pagotto U, Tschop M, Vicennati V, Manicardi E, Crcello A, Cacciar M, De lasio R, Pasquali R. Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome. J Endocrinol Invest. 2003. 26:629–634.
23. Ukkola O, Ravussian E, Jacobson P, Perusse L, Rankinen T, Tschop M, Heiman ML, Leon AS, Rao DC, Skinner JS, Wilmore JH, Sjostrom L, Bouchard C. Role of ghrelin polymorphism in obesity based on three different studies. Obes Res. 2002. 10:782–791.
24. Miraglia del Giudice E, Santoro N, Cirillo G, Raimondo P, Grandone A, D'Aniello A, Di Nardo M, Perrone L. Molecular screening of the ghrelin gene in Italian obese children: the Leu72Met variant is associated with an earlier onset of obesity. Int J Obes Relat Metab Disord. 2004. 28:447–450.
25. Ukkola O, Kesaniemi YA. Preproghrelin Leu72Met polymorphism in patients with type 2 diabetes mellitus. J Intern Med. 2003. 254:391–394.
26. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Novel modulator for endothelial adhesion molecules: adipocyte derived plasma protein adiponectin. Circulation. 1999. 100:2473–2476.
27. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002. 87:2764–2769.
28. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999. 257:79–83.
29. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsazawa Y, Chao CL, Chen CL, Tai TY, Chuang LM. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 2001. 86:3815–3819.
30. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001. 86:1930–1935.
31. Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K, Okazaki Y, Ishii T, Nishikai K, Saruta T. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond). 2002. 103:137–142.
32. Orio F Jr, Palomba S, Cascella T, Milan G, Mioni R, Pagano C, Zullo F, Colao A, Lombardi G, Vettor R. Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003. 88:2619–2623.
33. Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso D, Koliakos G. Serum adiponectin levels in women with polycystic ovary syndrome. Hum Reprod. 2003. 18:1790–1796.
34. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995. 270:27746–26749.
35. Stumvoll M, Tschritter O, Fritsche A, Staiger H, Renn W, Weisser M, Machicao F, Haring H. Association of the T-G polymorphism in adiponectin (exon2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes. 2002. 51:37–41.
36. Yang WS, Tsou PL, Lee WJ, Tseng DL, Chen CL, Peng CC, Lee KC, Chen MJ, Huang CJ, Tai TY, Chung LM. Allele-specific differential expression of a common adiponectin gene polymorphism related to obesity. J Mol Med. 2003. 81:428–434.
37. Yang WS, Hsiung CA, Ho LT, Chen YT, He CT, Curb JD, Grove J, Quertermous T, Chen YD, Kuo SS, Chuang LM. Sapphire Study Group. Genetic epistasis of adiponectin and PPARgamma2 genotypes in modulation of insulin sensitivity: a family-based association study. Diabeologa. 2003. 46:977–983.
38. Haap M, Machicao F, Stefan N, Thamer C, Tschritter O, Schnuck F, Wallwiener D, Stumvoll M, Haring HU, Fritsche A. Genetic determinants of insulin action in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2005. 113:275–281.
TOOLS
Similar articles